Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aaron T Gerds

Showing results (31-40 of 137) with videos related to

Pageof 14
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|March 8, 2022
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST StudyAaron T Gerds, Roger M Lyons, Philomena Colucci, et al.
Journal of Medical Economics|June 9, 2023
Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costsAaron T Gerds, Jingbo Yu, Anne Shah, et al.
Leukemia & Lymphoma|January 5, 2026
Pharmacy and transfusion costs of ruxolitinib and momelotinib in patients with myelofibrosis and anemiaAaron T Gerds, Jingbo Yu, Charles Tao, et al.
Journal of Managed Care & Specialty Pharmacy|October 3, 2024
Evaluating estimated health care resource utilization and costs in patients with myelofibrosis based on transfusion status and anemia severity: A retrospective analysis of the Medicare Fee-For-Service claims dataAaron T Gerds, Joseph Tkacz, Laura Moore-Schiltz, et al.
Journal of Comparative Effectiveness Research|August 2, 2023
Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia veraAaron T Gerds, Claudia Castro, Frank Snopek, et al.
Leukemia Research|June 14, 2025
A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosisMoshe Talpaz, Aaron T Gerds, Roger Lyons, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 19, 2012
Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDSAaron T Gerds, Ted A Gooley, Elihu H Estey, et al.
Leukemia Research|February 27, 2022
Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemiaNaveen Pemmaraju, Aaron T Gerds, Jingbo Yu, et al.
Acta Haematologica|January 10, 2022
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and OutcomesAaron T Gerds, Jingbo Yu, Robyn M Scherber, et al.
Hemasphere|October 7, 2022
Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world ImplicationsAaron T Gerds, Prithviraj Bose, Gabriela S Hobbs, et al.
Pageof 14

Showing results (31-40 of 137) with videos related to

Sort By:
Pageof 14
Clinical Lymphoma, Myeloma & Leukemia|March 8, 2022
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST StudyAaron T Gerds, Roger M Lyons, Philomena Colucci, et al.
Journal of Medical Economics|June 9, 2023
Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costsAaron T Gerds, Jingbo Yu, Anne Shah, et al.
Leukemia & Lymphoma|January 5, 2026
Pharmacy and transfusion costs of ruxolitinib and momelotinib in patients with myelofibrosis and anemiaAaron T Gerds, Jingbo Yu, Charles Tao, et al.
Journal of Managed Care & Specialty Pharmacy|October 3, 2024
Evaluating estimated health care resource utilization and costs in patients with myelofibrosis based on transfusion status and anemia severity: A retrospective analysis of the Medicare Fee-For-Service claims dataAaron T Gerds, Joseph Tkacz, Laura Moore-Schiltz, et al.
Journal of Comparative Effectiveness Research|August 2, 2023
Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia veraAaron T Gerds, Claudia Castro, Frank Snopek, et al.
Leukemia Research|June 14, 2025
A phase 2 study of itacitinib alone or in combination with low-dose ruxolitinib in patients with myelofibrosisMoshe Talpaz, Aaron T Gerds, Roger Lyons, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 19, 2012
Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDSAaron T Gerds, Ted A Gooley, Elihu H Estey, et al.
Leukemia Research|February 27, 2022
Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemiaNaveen Pemmaraju, Aaron T Gerds, Jingbo Yu, et al.
Acta Haematologica|January 10, 2022
Ruxolitinib Re-Treatment in Patients with Myelofibrosis: Real-World Evidence on Patient Characteristics and OutcomesAaron T Gerds, Jingbo Yu, Robyn M Scherber, et al.
Hemasphere|October 7, 2022
Treating Anemic Patients With Myelofibrosis in the New Janus Kinase Inhibitor Era: Current Evidence and Real-world ImplicationsAaron T Gerds, Prithviraj Bose, Gabriela S Hobbs, et al.
Pageof 14